Clinical Trials on Richter Transformation

Total 244 results

German CLL Study Group

Active, not recruiting

Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation (CLL-RT1)

Richter Transformation

Denmark, Germany, Austria
Institute of Hematology & Blood Diseases Hospital
Xian-Janssen Pharmaceutical Ltd.

Not yet recruiting

R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL (BDHRT001)

Richter Transformation

China
Niguarda Hospital

Recruiting

ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation (MOLTO)

CLL Transformation

Italy, Switzerland
M.D. Anderson Cancer Center
Amgen

Terminated

Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation

Hematopoietic/Lymphoid Cancer | Richter's Transformation

United States
Karyopharm Therapeutics Inc

Terminated

Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation (SIRRT)

Richter's Transformation

United States, Germany, United Kingdom, Spain, Poland
German CLL Study Group

Recruiting

Registry of the German CLL Study Group (CLL-Registry)

CLL | Leukemia, Prolymphocytic, T-Cell | SLL | Leukemia, Prolymphocytic, B-Cell | HCL | T-LGL Leukemia | Richter´s Transformation | NK-LGL Leukemia

Germany
Sierra Oncology LLC - a GSK company

Terminated

PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)

Richter's Transformation

United States
Bnai Zion Medical Center
Tel-Aviv Sourasky Medical Center

Recruiting

A Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter's Syndrome;

Richter's Syndrome

Israel
University of California, San Diego

Completed

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

CLL | Richter's Syndrome

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Richter Transformation Lymphoma

Poland, United States, Canada, Chile, China, Estonia, Israel, Italy, Korea, Republic of, Spain, Sweden, Turkey, Czechia, Germany, Brazil, Portugal, Ireland, Singapore, United Kingdom, Japan, Peru
University of Oxford
GlaxoSmithKline; Cancer Research UK; Oxford University Hospitals NHS Trust; NCRI...

Completed

Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome (CHOP-OR)

Richter's Syndrome

United Kingdom
Kite, A Gilead Company

Recruiting

Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25)

Relapsed/Refractory Waldenstrom Macroglobulinemia | Relapsed/Refractory Richter Transformation | Relapsed/Refractory Burkitt Lymphoma | Relapsed/Refractory Hairy Cell Leukemia

United States, Spain, Germany, Italy, France, Netherlands, Switzerland, Austria
Acerta Pharma BV

Terminated

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

DLBCL | Richter Syndrome

United Kingdom, United States
French Innovative Leukemia Organisation
Amgen

Completed

BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

Richter Syndrome

France
German CLL Study Group
Hoffmann-La Roche

Terminated

Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation (CLLTX1)

Chronic Lymphocytic Leukemia | Richter's Transformation

Germany
TG Therapeutics, Inc.

Terminated

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

B-cell Non Hodgkin Lymphoma | Richter's Transformation

United States
French Innovative Leukemia Organisation
Hoffmann-La Roche

Recruiting

Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome (GLORIFY)

Richter Syndrome

France
Dana-Farber Cancer Institute
Genentech, Inc.

Recruiting

A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome

Richter Syndrome

United States
Northwell Health
Pharmacyclics LLC.

Terminated

Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

Richter Syndrome

United States
Central Hospital, Nancy, France
Institut National de la Santé Et de la Recherche Médicale, France; French Innovative...

Recruiting

Genomic and Proteomic Study of Richter Syndrome (CGPSR) (CGPSR)

Richter Syndrome

France
M.D. Anderson Cancer Center
Sanofi

Completed

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

Leukemia | Richter's Transformation

United States
Newave Pharmaceutical Inc

Recruiting

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Acute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Acute Lymphocytic Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Small Lymphocytic Lymphoma | Chronic Myelomonocytic Leukemia-2 | Richter Transformation | T-cell-prolymphocytic Leukemia and other conditions

United States
Acerta Pharma BV

Active, not recruiting

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Small Lymphocytic Lymphoma | Richter's Syndrome

United States, United Kingdom, Italy
Christine Ryan
Genentech, Inc.

Recruiting

A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation

Chronic Lymphocytic Leukemia | Richter's Transformation

United States
BeiGene

Recruiting

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Relapsed Follicular Lymphoma | Refractory Small Lymphocytic Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Diffuse Large B-cell Lymphoma | Transformed Non-Hodgkin Lymphoma | Relapsed... and other conditions

China, Australia
Pharmacyclics LLC.
Ohio State University

Completed

Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL (PCYC-1109-CA)

B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Richter's Transformation | Prolymphocyctic Leukemia

United States
Genmab
AbbVie

Recruiting

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1)

Small Lymphocytic Lymphoma | Richter's Syndrome | Relapsed/Refractory Chronic Lymphocytic Leukemia

United States, Belgium, Netherlands, Spain, Italy, Australia, Israel, France, Denmark, Czechia, Germany, United Kingdom
German CLL Study Group

Completed

Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)

Chronic Lymphocytic Leukemia

Germany
M.D. Anderson Cancer Center
Loxo Oncology, Inc.; The Leukemia and Lymphoma Society

Recruiting

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Leukemia

United States
VelosBio Inc., a subsidiary of Merck & Co., Inc...

Completed

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

Follicular Lymphoma | Acute Myeloid Leukemia | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Acute Lymphoid Leukemia | Richter Transformation Lymphoma | Lymphoplasmacytoid Lymphoma | T-cell Non-Hodgkin...

United States
Transplant Biomedicals, S.L.

Unknown

Prospective, Single-Arm, Study to Assess the Safety and Performance of the TB1-K Device for Organ Preservation in Donor Kidneys for Transplantation (EMERGE)

Kidney Preservation and Transportation

Spain
University of Birmingham
Acerta Pharma, LLC; Bloodwise

Recruiting

A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome (STELLAR)

Richter Syndrome

United Kingdom
Sun Yat-sen University

Unknown

Cavernous Transformation of Portal Vein： Etiology, Diagnosis, Management and Prognosis

Portal Vein, Cavernous Transformation Of

China
University of Pennsylvania
Lyft, Inc.

Completed

The Impact of Rideshare Transportation Services on Appointment Adherence

Primary Health Care | Social Determinants of Health | Transportation | Appointments and Schedules

United States
Kochi University

Completed

Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids

Liver Cancer

Japan
Sun Yat-sen University

Unknown

Percutaneous Transhepatic Intrahepatic Portosystemic Shunt for Treatment of Portal Vein Occlusion With Symptomatic Portal Hypertension After Splenectomy

Hypertension, Portal | Portal Vein, Cavernous Transformation Of

China
Sun Yat-sen University

Unknown

Interventional Radiology for the Treatment of Symptomatic Portal Hypertension in Patients With Cavernous Transformation of Portal Vein

Hypertension, Portal | Portal Vein, Cavernous Transformation Of

China
Zhejiang DTRM Biopharma

Recruiting

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Follicular Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Richter's Transformation | Relapsed Chronic Lymphocytic Leukemia

United States
University of Bern
ETH Zurich; University of St.Gallen

Completed

Design and Implementation of a Drunk Driving Detection System (DRIVE)

Alcohol Drinking | Impaired Driving | Transportation Accidents | Drunk Driving

Switzerland
TG Therapeutics, Inc.

Active, not recruiting

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Follicular Lymphoma | Marginal Zone Lymphoma | DLBCL | CLL | MCL | Indolent Lymphoma | Richter's Transformation | SLL | Mediastinal Large B-cell Lymphoma | Aggressive Lymphoma

United States
TG Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center

Completed

Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation

Chronic Lymphocytic Leukemia | Richter Syndrome

United States
Vion Pharmaceuticals

Completed

VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders

Lymphoma | Leukemia

United States
Nanfang Hospital of Southern Medical University

Recruiting

Decitabine and HQP1351-based Chemotherapy Regimen for the Treatment Advanced CML (Case-Only)

Chronic Myeloid Leukemia in Myeloid Blast Crisis | Chronic Myeloid Leukaemia Transformation | Chronic Myeloid Leukemia - Accelerated Phase | Chronic Myeloid Leukemia in Lymphoid Blast Crisis

China
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)

Richter Syndrome | Mediastinal Large B-cell Lymphoma
Nurix Therapeutics, Inc.

Recruiting

A Study of NX-1607 in Adults With Advanced Malignancies

Cervical Cancer | Gastric Cancer | Head and Neck Squamous Cell Carcinoma | Non-small Cell Lung Cancer (NSCLC) | Metastatic Urothelial Carcinoma | Ovarian Cancer, Epithelial | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Triple Negative Breast Cancer (TNBC) | Malignant Pleural Mesothelioma... and other conditions

United States, United Kingdom
Weill Medical College of Cornell University
Genentech, Inc.

Recruiting

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Chronic Lymphocytic Leukemia | Richter Syndrome

United States
The First Affiliated Hospital of Xiamen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma | Bevacizumab | TACE | Adebrelimab | Transformation

China
Beijing University of Chinese Medicine
Harvard Medical School (HMS and HSDM); China Academy of Chinese Medical Sciences and other collaborators

Recruiting

Risk Assessment and Syndrome Evolution Models for Chronic Atrophic Gastritis Malignant Transformation

Risk Assessment of Chronic Atrophic Gastritis Malignant Transformation

China
China Medical University Hospital

Completed

Astragalus Membranaceus for Brain Edema Induced by Hemorrhagic Stroke

Stroke | Hemorrhagic Transformation Due to Acute Stroke
BeiGene

Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Burton Tyrosine Kinase-Targeted Protein-Degrader

Follicular Lymphoma | Waldenström Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Richter's Transformation | DLBCL Unclassifiable

China

Clinical Trials on Richter Transformation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations